3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 1
14
Phase 3
8
Phase 1/2
5
Phase NA
2
Phase 2/3
2
Phase 4
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
4
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoid Interstitial Pneumonia
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Carcinoma
1
Endometrial Neoplasms
1
Carcinoma
1
Advanced Solid Tumor
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
Standard of Care
3
Oxaliplatin
3
Melatonin
3
Gemcitabine
3
Fluorouracil
3
Drug Therapy
3
Ciprofloxacin
3
Capecitabine
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
alectinib
2
Water
2
Vemurafenib
2
Trastuzumab
2
Sirolimus
2
Saline Solution
2
Pemetrexed
2
Methylphenidate
2
Lidocaine
2
Leucovorin
2
Immunoglobulins, Intravenous
2
Docetaxel
2
Dexmedetomidine
2
Cisplatin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasms
×
atezolizumab
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled